Additional Relevant Details European Medicines Agency (EMA) has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML). AML can be a rapidly progressing cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. Venetoclax is being developed by AbbVie in partnership with Genentech and Roche.